Challenges in analytical aerosol methods for high payload inhalation products

HFA152a green propellant capabilities

With evolving regulations and a growing push for sustainability, switching pressurized metered-dose inhalers (pMDIs) to green propellants is becoming increasingly essential. One of the most promising low global warming potential (GWP) options is HFA152a. In this white paper, we share insights on transitioning to HFA152a. Download your copy to discover: An overview of sustainability regulations […]

Leading the way in low-GWP propellants

As regulations surrounding inhalation device sustainability evolve, we help you streamline the process of transitioning to low global warming potential (GWP) propellants. Clinical supply for green propellants HFA152a and HFO1234ze is already available, with commercial scale available this year and plans for further expansion. Download this information sheet to dive deeper into our low-GWP propellant […]

Opportunities and considerations for inhaled biologics

Respiratory biologics is an emerging area in pharmaceutical development, accounting for approximately 10% of biologics currently in the pipeline. These innovative treatments offer significant benefits across various therapeutic areas. Gain deeper insights into the development of inhaled biologics with this comprehensive presentation by experts from Kindeva Drug Delivery, Aerogen Pharma, and Cystetic Medicines. Highlights include: […]

Pulmonary & nasal delivery capabilities 

Get an overview of our pulmonary & nasal delivery capabilities, including:  Customized approach to determining the right device for your drug  Pulmonary & nasal platform technologies: pressurized metered-dose inhaler (pMDI), dry power inhaler (DPI), soft-mist inhaler (SMI), nebulizer, and nasal spray  Green propellant innovations  Experience bringing complex generics to market  Expansive capabilities across state-of-the-art facilities […]

Optimizing spray formation of low GWP metered dose inhalers – Unlocking product performance understanding

In response to growing concerns about sustainability, switching to more environmentally friendly pMDI propellants has become a high priority for the pharmaceutical industry. Since inhalation devices contribute 3% of global emissions, this is an important step. In addition to being a part of a greener future, transitioning to a low GWP propellant now positions companies […]

Missed ss at DDL? Unlock pulmonary & nasal insights with our presentations 

Kindeva Drug Delivery presented cutting-edge advancements in pulmonary & nasal development and manufacturing at the Drug Delivery to the Lungs (DDL) conference on December 6-8, 2023. Across eight posters and podium presentations, we highlighted strategies for switching to green propellant formulations while preserving product performance, among a variety of other topics. If you missed any […]

The pMDI dilemma: managing patient needs, human health, and the planet

Green propellants: The impact of proposed regulations